跳至主要内容
临床试验/NCT00648999
NCT00648999已完成4 期

Phase IV, Non Randomized Study in ARV Experienced Patients Under Switch Therapy With Kaletra

AbbVie (prior sponsor, Abbott)13 个研究点 分布在 1 个国家目标入组 207 人开始时间: 2003年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
207
试验地点
13
主要终点
Quality of Life

研究概览

简要总结

To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
17 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HIV Infected subjects
  • Subjects failing in current HIV treatment, or
  • Subjects with a viral load < 400 copies/mL and not tolerating their current HIV treatment.

排除标准

  • Subject is currently participating in another clinical study or has participated in another clinical study within 30 days prior to screening visit
  • Subject is pregnant

研究组 & 干预措施

1

Active Comparator

干预措施: lopinavir/ritonavir (Drug)

2

Active Comparator

干预措施: lopinavir/ritonavir (Drug)

结局指标

主要结局

Quality of Life

时间窗: Baseline, Week 4, Week 24 and Week 48

CD4

时间窗: Baseline, Week 24 and Week 48

次要结局

  • Adverse Event Monitoring(Baseline, Week 4, Week 24 and Week 48)

研究者

发起方
AbbVie (prior sponsor, Abbott)
申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验